NervGen In Spotlight As It Approaches Clinical Proof Of Concept Readout For Spinal Cord Regeneration
NervGen is engaged in groundbreaking research in spinal cord injury treatment. Read here for an update on the research's ...
Zacks.com on MSN23h
Biotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & More
It was a busy week in the biotech sector, with many regulatory and pipeline updates. Neumora Therapeutics NMRA plummeted on ...
Cullinan Therapeutics' CLN-978 And Zipalertinib Look Promising In NSCLC
Cullinan offers promising oncology and autoimmune products, strong financials, and potential for growth, making it a ...
Taiwan News6h
ProMIS Neurosciences Initiates Phase 1b Clinical Trial (PRECISE-AD) in Alzheimer’s Disease
ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on developing precision therapies for neurodegenerative diseases, today announced the initiation of its Phase 1b ...
STAT1h
Up and down the ladder: The latest comings and goings
From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...
Canada's Imperial Oil Says Senior Executive to Leave for Exxon Mobil
(Reuters) - Canadian oil refiner Imperial Oil said on Friday senior executive Sherri Evers will join major shareholder Exxon ...
Yahoo Finance18h
Sichuan Hebang Biotechnology Corporation Limited (603077.SS)
As of 1:39:37 PM GMT+8. Market Open.